SciRhom raises €16.0M Seed round
25 November 2021· Martinsried, Germany· health, biotech, immunology, therapeutics, b2b, deep_hardware
The additional funding brings the total seed round to 16 million EUR to accelerate the development of first-in-class TACE/ADAM17 antibodies toward clinical trials.
Investors
LeadHospital for Special Surgery
Also participating
High-Net-Worth Individuals
About SciRhom
Stage
Series A
Headquarters
Martinsried, Germany
Founded
2016
Team Size
21–50
Sectors
healthbiotechimmunologytherapeuticsb2bdeep_hardware